Pfizer goes to court to stop Novo Nordisk bid for Metsera

1 November 2025

US pharma giant Pfizer (NYSE: PFE) revealed on Friday that it has filed a lawsuit against Metsera (Nasdaq: MTSR), its board of directors, and Denmark’s Novo Nordisk (NOV: N) in the Delaware Court of Chancery.

The legal action comes after Novo Nordisk said last Thursday that it has made an unsolicited bid for Metsera, offering at least $6.5 billion to Metsera shareholders, with the possibility of that rising to a total of $9 billion if certain targets are met over time.

The Pfizer lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera worth up to $7.3 billion announced late September.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK